Postersession I

Programme

• • Poster
  • P-1-1

  The DZIF Transplant Cohort e.V.

  • Dr. Daniela Schindler (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-2

  Antibiotic susceptibility study of carriage and clinical strains of N. meningitidis in the health districts of Kaya and Boussouma in the central-northern region of Burkina Faso from 2016-2017

  • Dr. Emmanuel SAMPO (Ouagadougou/ BF)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-3

  Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions

  • Dr. Bastian Seelbinder (Jena/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-4

  ULBP2-expressing HCMV mutants modulate NKG2D expression and function on NK and CD8⁺ T cells

  • Greta Meyer (Hannover/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-5

  The added value of (1,3)-β-D-glucan for the diagnosis of Invasive Candidiasis in ICU patients: a prospective cohort study

  • Dr. Flaminia Olearo (Hamburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-6

  SARS-CoV-2 induced B cells generate an anticipatory memory against new virus variants and re-engage in COVID-19 vaccine responses

  • Dr. Matthias Bruhn (Hannover/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-7

  Outer membrane vesicle of Klebsiella pneumoniae decrease bactericidal properties of alveolar macrophages

  • Dr. Mohammad Estiri (Giessen/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-8

  Invasive fungal disease in chronic liver transplant failure – an underestimated burden

  • Aleksandra Puzalkova (Heidelberg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-9

  Interim analysis of a longitudinal study on sexual health in females

  • Dr. Nadja Käding (Lübeck/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-10

  FGS and HPV prevalence and risk factors in rural Madagascar: implications for women's health services in limited resource settings

  • Jean-Marc Kutz (Hamburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-11

  Microbiota context dependent dual protective role of Klebsiella oxytoca against Salmonella infection

  • Dr. Lisa Osbelt (Braunschweig/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-12

  Plasma protein signature reveals chronic-inflammatory and angiogenic processes in addition to sustained immune cell differentiation in convalescent severe COVID-19 patients

  • Dr. Jenny Franziska Kühne (Hannover/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-13

  The sporulation pathway as a pathoblocker target in Clostridioides difficile

  • Christopher Birk (Würzburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-14

  Pulmonary nucleotide transfection for antiviral therapy

  • Achim Biesel (Saarbrücken/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-15

  Complex in vitro models and advanced delivery systems for improving drug transport across biological barriers delimiting bacterial bioavailability of anti-infective drugs

  • Prof. Dr. Claus-Michael Lehr (Saarbrücken/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-16

  Interferon-Gamma-Release-Assay (IGRA) is a reliable and cost-effective method for the determination the T-cell immune response against SARS-CoV-2 directly ex vivo

  • Marta Minic (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-17

  Potentiating the efficacy of antibiotics in Escherichia coli by nanorods

  • Mohamed Ashraf Mostafa Kamal (Saarbrücken/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-18

  Human induced pluripotent stem cell (hiPSC‐) -derived lung organoids for disease modelling

  • Margarida Maria Barroso (Giessen/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-19

  Neutrophil efferocytosis reprograms mitochondrial metabolism to lock alveolar macrophages in a pro-resolution phenotype at the expense of bacterial control

  • Dr. Julian Better (Marburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-20

  Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: a scoping review

  • Lydia Holtgrewe (Heidelberg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-21

  Assessing dynamics of respiratory syncytial virus from 2020-2022/23 in Germany in an epidemic panel (MuSPAD)

  • Dr. Manuela Harries (Braunschweig/ DE)
  • Dr. Carolina J. Klett-Tammen (Braunschweig/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-22

  The role of paleoviral sequences of Ebola virus in immune tolerance

  • Christoph Henkel (Hamburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-23

  A targeted mutagenesis screen of the hepatitis B virus envelope protein L implicates a structurally important domain for fusion

  • Dr. Britta Möhl-Meinke (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-24

  EVREA-Phage: eradication of intestinal vancomycin resistant Enterococcus faecium through phage therapy

  • Dr. Filipa Martins (Braunschweig/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-25

  Fever in focus: sex differences among pediatric fever visits in a Ghanaian birth cohort

  • Lydia Rautman (Hamburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-26

  Generation of monoclonal antibodies targeting fiberknob that neutralize HAdV-5 infection

  • Dr. Britta Möhl-Meinke (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-27

  Next generation of LMP2A-targeting engineered TCR-recombinant T cells with inducible expression of IL-18 as promising approach for EBV-associated malignancies

  • Philip Mausberg (Hannover/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-28

  Overcoming immune escape in EBV-associated malignancies by understanding the two levels of immunosuppression: the tumor microenvironment and iatrogenic immunosuppression

  • Sven Stoll (Hannover/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-29

  Evaluation von Diagnostik und Therapie der Pneumonie zur Verbesserung der Behandlungsqualität

  • David Leber (Hamburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-30

  Genome-wide association analysis identifies three loci and one HLA allele associated with post-TB lung function in African adults

  • Luming Lin (Munich/ DE)
  • Kathrin Held (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-31

  Analysis of transcriptional changes upon Respiratory Syncytial Virus infection of human airway epithelial cells

  • Dr. Sibylle Haid (Hannover/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-32

  Assessing the activation profile of Mycobacterium tuberculosis-specific T cells as a surrogate marker for in vivo disease activity in tuberculosis household contacts

  • Kathrin Held (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-33

  Impact of non-selective beta-blockers on the development of spontaneous bacterial peritonitis (SBP), hepatic decompensation and survival after transjugular intrahepatic portosystemic shunt (TIPS-) insertion

  • Prof. Benjamin Maasoumy (Hannover/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-34

  Untangling the complex relationship between cytomegalovirus and tuberculosis in children investigated for TB

  • Alia Razid (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-35

  Comparative mathematical model of RSV infection: pre, during, and post COVID-19 pandemic analysis in Germany

  • Dr. Isti Rodiah (Braunschweig/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-36

  Scenarios for the SARS-CoV-2 pandemic 2023 in Germany

  • Dr. Isti Rodiah (Braunschweig/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-37

  Impact of mucosal adjuvants on gut microbiome composition in prophylactic vaccination strategies against H. pylori.

  • Dr. Dharmesh Singh (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-38

  A combination of direct acting and host-directed antivirals dramatically suppresses SARS-CoV-2 and MERS-CoV replication

  • Lucie Sauerhering (Marburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-39

  Brain specific immune responses to Nipah- and Ebola virus infection in in-vitro and ex-vivo models

  • Dr. Alexandra Kupke (Marburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-40

  Establishment and characterization of lethal and non-lethal animal models for Marburg virus

  • Michael Klüver (Marburg/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-41

  Clinical signs of early inflammation can predict a prolonged course of Infectious Mononucleosis in children, adolescents, and young adults – data from a prospective clinical observational study in Germany (IMMUC study)

  • Kirstin Mittelstraß (Munich/ DE)

   Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
• • Poster
  • P-1-42

  Improved clinical outcome of Covid-19 in haematologic malignancy patients receiving a fourth dose of anti-SARS-Cov-2 vaccine: an epicovideha report

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-43

  Molnupiravir compared to nirmatrelvir/ritonavir for Covid-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the epicovideha registry

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-44

  Nirmatrelvir/ritonavir in Covid-19 patients with haematological malignancies: a report from the epicovideha registry

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-45

  Pre-exposure immunization by tixagevimab/cilgavimab in hematological malignancy and Covid-19 in the epicovideha registry

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-46

  The current state of laboratory mycology in Asia/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-47

  Laboratory capacities to diagnose and treat invasive fungal infections in Europe: results from the ECMM survey

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-48

  Immunogenicity and reactogenicity of a first booster with BNT162B2 or full-dose of MRNA-1273: a randomised trial in adults ≥75 years (EU-COVAT-1) from the vaccelerate consortium

  • Dr. Philipp Koehler (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-49

  Multipathogen antigen test kit (MAK-5) - distribution and frequency of viral respiratory diseases in Germany among volunteers in the vaccelerate registry

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-50

  Poliovirus vaccination status among adult participants in the vaccelerate volunteer registry

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-51

  Establishing the vaccelerate site network: capacity mapping of clinical trial sites

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-52

  The first two years of the European vaccelerate volunteer registry

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-53

  Country-specific needs, ethics and regulatory requisites related to implementing a trial volunteer registry across Europe: the vaccelerate volunteer registry experience

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-54

  The Argentinian Landscape of mycological diagnostic capacity and treatment

  • Fernando Riera (Córdoba/ AR)

   Immune Prevention and Therapy
• • Poster
  • P-1-55

  Laboratory capacities to diagnose and treat invasive fungal infections in Austria, Germany and Switzerland

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-56

  Laboratory capacities to diagnose and treat invasive fungal infections in Italy: local results from an ECMM survey

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-57

  Laboratory capacities to diagnose and treat invasive fungal infections in Nordic countries: results from an NSMM and ECMM survey

  • Dr. Jon Salmanton-García (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-58

  Targeting Pseudomonas aeruginosa LasB by patient-derived monoclonal antibodies

  • Dr. Alexandra Albus (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-59

  A novel high-throughput Haemagglutinin binding assay to generate comprehensive Influenza virus escape maps

  • Leon Ullrich (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-60

  Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escape

  • Dr. Christoph Kreer (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-61

  Recombinant mosaic HBV capsid particles foster adaptive immunity against the most prevalent HBV genotypes by therapeutic vaccination

  • Shubhankar Ambike (Munich/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-62

  RNA aptamers derived from the Hepatitis B Virus RNA element epsilon efficiently inhibit HBV replication in vitro

  • Dr. Jürgen Beck (Freiburg/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-63

  HCMV neutralization by broad antibody targeting

  • Dr. Matthias Zehner (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-64

  NRF2-independent inhibition of human coronaviruses by "NRF2 activators"

  • Dr. Fakhar Waqas (Hannover/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-65

  Identification of human antibodies enhancing the innate immune response against Pseudomonas aeruginosa

  • Julia Kutschera (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-66

  Characterization of human papillomavirus-derived peptide binding to HLA in acidic tumor milieu

  • Dr. Maria Bonsack (Heidelberg/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-67

  Longitudinal Dynamics Of SARS-CoV-2 Spike-specific Antibody Responses In Patients On Waiting List And After Lung Transplantation

  • Dr. Jenny Franziska Kühne (Hannover/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-68

  Duration of protection from pneumonia after pneumococcal vaccination in haemodialysis patients – interim analysis of the DOPPIO study

  • Dr. Sibylle C. Mellinghoff (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-69

  Translation of advanced cell therapies for HIV-positive patients into the clinic

  • Dr. Lea Isabell Schwarze (Hamburg/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-70

  Effects of bile acids on NK cells in HDV patients under Bulevirtide treatment

  • Po-Chun Chen (Hannover/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-71

  Itaconate and its downstream product mesaconate exhibit overlapping and distinct immunometabolic effects in macrophage

  • Dr. Wei He (Braunschweig/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-72

  Soluble immunological markers correlate with acute inflammation and clinical severity in severe hepatitis ("hepatitis flares")

  • Roni Souleiman (Hannover/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-73

  Vaccine to Inhibit Autochthonous Transmission of Hepatitis (VaccinATE)

  • Isabella Hrabal (Greifswald - Insel Riems/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-74

  Dual-active oxadiazoles targeting the Mycobacterium tuberculosis ESX-1 secretion system and boosting ethionamide activity

  • Dr. Michael Dal Molin (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-75

  Blocking viral entry reduces the frequency of Hepatitis Delta virus infected hepatocytes in human liver biopsies

  • Dr. Lena Allweiss (Hamburg/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-76

  Identification of a broad and potent NTD-targeting SARS-CoV-2 antibody using an extended pseudovirus panel

  • Finn Teipel (Cologne/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-77

  Correlates of humoral immune protection in acute resolving and chronic HCV infection

  • Dr. Dorothea Bankwitz (Hannover/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-79

  Intracellular mRNA:miRNA profiling after rVSV-ZEBOV vaccination

  • Monika Rottstegge (Hamburg/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-80

  Pandemieimpfstoffherstellung in pandemiefreien Zeiten

  • Christian Marx (Langen/ DE)

   Immune Prevention and Therapy
• • Poster
  • P-1-81

  Innate immune modulation by HBV and HDV induced extracellular vesicles

  • Prof. Stephanie Jung (Bonn/ DE)

   Chronic Infections
• • Poster
  • P-1-82

  Preserved frequency and cytotoxicity of HIV-specific follicular CD8 T cells associates with reduced viral reservoir in individuals treated during primary HIV infection

  • PD Dr.med. Julia Roider (Munich/ DE)

   Chronic Infections
• • Poster
  • P-1-83

  Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions

  • Valerie Ohlendorf (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-84

  Long-term outcome of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International Network (HDIN)

  • Dr. Anika Wranke (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-85

  Prevalence, genotype distribution and risk factors of oropharyngeal human papilloma virus (HPV) infection over time in transplant recipients (DZIF-Transplantation Cohort)

  • PD Dr. Tina Ganzenmueller (Tübingen/ DE)

   Chronic Infections
• • Poster
  • P-1-86

  Multiplex serology to differentiate pan-hepatitis virus-specific antibody responses in vaccinated and infected individuals

  • Dr. Tanja Michel (Reutlingen/ DE)

   Chronic Infections
• • Poster
  • P-1-87

  Disrupting Kaposi's sarcoma-associated herpesvirus (KSHV) latent replication with a small molecule inhibitor and PROTACs

  • Aylin Berwanger (Saarbrücken/ DE)
  • Dr. Saskia C. Stein (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-88

  HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection

  • Dr. Lisa Sandmann (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-89

  NRF2 activators inhibit hepatitis E virus propagation in vitro

  • Fenja Laue (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-90

  Ongoing low-level p24 production in long-term ART-treated individuals

  • Dr. Enrico Richter (Bonn/ DE)
  • Prof. Hendrik Streeck

   Chronic Infections
• • Poster
  • P-1-91

  An AAV-based RNAi and CRISPR vector system to multilaterally combat chronic HBV infections

  • Nico Fischer (Heidelberg/ DE)

   Chronic Infections
• • Poster
  • P-1-92

  High replication fitness of the hepatitis C virus, mediated by a small region in the non-structural protein 5A, is an evolutionary selection factor and causes direct viral pathogenesis in liver transplant patients

  • Prof. Dr. Volker Lohmann (Heidelberg/ DE)

   Chronic Infections
• • Poster
  • P-1-93

  Thioxothiazolo[3,4-a]quinazoline derivatives inhibit the human cytomegalovirus alkaline nuclease

  • Tianyu Zhang (Hamburg/ DE)

   Chronic Infections
• • Poster
  • P-1-94

  Latent CMV and SARS-CoV2: mutually detrimental or beneficial?

  • Dr. Upasana Kulkarni (Braunschweig/ DE)

   Chronic Infections
• • Poster
  • P-1-95

  The impact of cirrhosis on the regeneration of the inflammatory milieu after HCV cure

  • Moana Witte (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-96

  A soluble plasma factor of post-COVID syndrome patients impairs innate immune signaling

  • Dr. Lea Picard (Cologne/ DE)

   Chronic Infections
• • Poster
  • P-1-97

  Vaginal microbiome variability in women affected by female genital schistosomiasis and human papillomavirus infection: a cross-sectional study from Madagascar

  • Jana Hey (Hamburg/ DE)

   Chronic Infections
• • Poster
  • P-1-98

  The impact of chronic schistosomiasis on co-infections with dengue virus in Madagascar

  • Jana Hey (Hamburg/ DE)

   Chronic Infections
• • Poster
  • P-1-99

  Polyfunctional hepatitis D virus-specific CD4⁺ T-cell responses are detectable during low viremia time-points in patients chronically infected with the hepatitis D virus

  • Reem Hoblos (Hannover/ DE)
  • Dr. med. Helenie Kefalakes (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-100

  Generation of a pan-genotypic MVA vector for targeting chronic hepatitis B via therapeutic vaccination

  • Dr. Anna D. Kosinska (Munich/ DE)

   Chronic Infections
• • Poster
  • P-1-101

  Altered immune cell phenotype in the gut associated lymphatic tissue (GALT) of post-Covid patients: implications for pathogenesis

  • Dr. Lea Picard (Cologne/ DE)

   Chronic Infections
• • Poster
  • P-1-102

  HBV RNA in the natural course of HBV/HDV coinfection

  • Dr. Lisa Sandmann (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-103

  DNA methyltransferase inhibition improves the effect of immune checkpoint inhibitors to restore exhausted HBV-specific T cell responses

  • Melanie Urbanek-Quaing (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-104

  Single cell analysis of hepatitis C virus (HCV) and heterologous virus-specific CD8+ T cell responses in patients with chronic HCV infection

  • Jasmin Mischke (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-105

  Elevated levels of genome replication of Hepatitis C Virus are associated with response to interferon treatment but do not correlate with viral serum titers or DAA therapy failure

  • Tomke Arand (Heidelberg/ DE)

   Chronic Infections
• • Poster
  • P-1-106

  Strong reduction of HDV infected cells in HBV/HDV infected humanized mice receiving pegylated interferon-alpha in combination with Bulevirtide

  • Dr. Tassilo Volz (Hamburg/ DE)

   Chronic Infections
• • Poster
  • P-1-107

  Klebsiella pneumoniae brain abscess caused by dissemination of a virulent subpopulation from a urinary tract infection

  • Prof. Dr. Christoph Ernst (Cologne/ DE)

   Chronic Infections
• • Poster
  • P-1-108

  First-in-class LMP1-TRAF2 interaction inhibitors block Epstein-Barr virus oncoprotein LMP1-induced signaling and interfere with LCL and PTLD survival

  • Fabian Giehler (Neuherberg/ DE)

   Chronic Infections
• • Poster
  • P-1-109

  The optimized LMP1-TRAF2 inhibitor lead compound SBL563 blocks LMP1 signaling and promotes cell death in EBV-induced tumor cells with high efficiency

  • Alice Randon (Neuherberg/ DE)

   Chronic Infections
• • Poster
  • P-1-110

  In depth characterization of follicular HIV-specific CD8 T cells in human peripheral blood

  • Danni Wang (Munich/ DE)

   Chronic Infections
• • Poster
  • P-1-111

  CD39 expression identifies tissue-resident CD8+ T cells with exhausted phenotype in lymph nodes of untreated HIV-positive individuals

  • Leon Cords (Hamburg/ DE)

   Chronic Infections
• • Poster
  • P-1-112

  Prevalence of HCV infections in Germany from an epidemic panel (MuSPAD)

  • Zahra Ghodratian (Frankfurt a. M./ DE)

   Chronic Infections
• • Poster
  • P-1-113

  Establishment and clinical validation of a laboratory developed hexaplex digital PCR assay for absolute quantification of EBV, CMV, VZV, HSV 1, HSV 2 and beta-globin from human tissue samples

  • Lisa Sophie Pflüger (Hamburg/ DE)

   Chronic Infections
• • Poster
  • P-1-114

  Neutrophil associated markers to predict postTB lung impairment

  • Christoph Leschczyk (Borstel/ DE)

   Chronic Infections
• • Poster
  • P-1-115

  HBV-specific T cell immunity in tissue and circulation: a system level analysis

  • Sainitin Donakonda (Munich/ DE)

   Chronic Infections
• • Poster
  • P-1-116

  High resolution MALDI MS Imaging in tuberculosis research – investigation of drug distribution and granuloma-penetration of anti-tuberculosis drugs

  • Eva-Maria Stemp (Bayreuth/ DE)

   Chronic Infections
• • Poster
  • P-1-117

  Economic evaluation to inform target product profile development for tuberculosis treatment monitoring

  • Dr. Florian M. Marx (Heidelberg/ DE)

   Chronic Infections
• • Poster
  • P-1-118

  Predicting HCMV reactivation and acute graft versus host disease in HSCT patients

  • Penelope C. Kay-Fedorov (Hannover/ DE)

   Chronic Infections
• • Poster
  • P-1-119

  Novel Small Chemical Compounds Blocking Herpes Simplex Virus Assembly

  • Prof. Dr. rer. nat. Beate Sodeik (Hannover/ DE)

   Chronic Infections